Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
Products tagged as [GENERIC] have had a generic equivalent approved for at least one strength of the product.
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5034394 [Extended 905 days (2.5 years)] Therapeutic nucleosides Claim Types: Compound; Composition Comments: For its TRIZIVIR listing, the expiration date of this patent does not include the extension | JUN 18,2012 *PED | |
| Pat. No. 5089500 Therapeutic nucleosides Claim Types: Method of use | DEC 26,2009 *PED | U-248: Treatment of HIV |
| Pat. No. 6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections Claim Types: Composition; Method of use | NOV 14,2018 *PED | U-65: Method of treatment of a patient infected with HIV |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | AUG 02,2007 | D-40: Once-a-day dosing regimen |
ABACAVIR SULFATE (SOLUTION) ZIAGEN
Drug Classes: ANTIVIRALS
NDA Applicant: GLAXOSMITHKLINE NDA No.: 020978 Prod. No.: 001 RX (EQ 20MG BASE/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5034394 [Extended 905 days (2.5 years)] Therapeutic nucleosides Claim Types: Compound; Composition Comments: For its TRIZIVIR listing, the expiration date of this patent does not include the extension | JUN 18,2012 *PED | |
| Pat. No. 5089500 Therapeutic nucleosides Claim Types: Method of use | DEC 26,2009 *PED | U-248: Treatment of HIV |
| Pat. No. 6294540 Carbocyclic nucleoside hemisulfate and its use in treating viral infections Claim Types: Composition; Method of use | NOV 14,2018 *PED | U-65: Method of treatment of a patient infected with HIV |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | AUG 02,2007 | D-40: Once-a-day dosing regimen |
ABACAVIR SULFATE; LAMIVUDINE (TABLET) EPZICOM
Drug Classes: ACE INHIBITORS
NDA Applicant: SMITHKLINE BEECHAM NDA No.: 021652 Prod. No.: 001 RX (EQ 600MG BASE;300MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5034394 DS* DP* [Extended 905 days (2.5 years)] Therapeutic nucleosides Claim Types: Compound; Composition Comments: For its TRIZIVIR listing, the expiration date of this patent does not include the extension | JUN 18,2012 *PED | |
| Pat. No. 5047407 DS* DP* [Extended 282 days* (0.8 years)] 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties Claim Types: Compound; Composition | MAY 17,2010 *PED | U-257: Treatment of HIV infection |
| Pat. No. 5089500 Therapeutic nucleosides Claim Types: Method of use | DEC 26,2009 *PED | U-257: Treatment of HIV infection |
| Pat. No. 5905082 DS* DP* Crystalline oxathiolane derivatives Claim Types: Composition; Method of use | NOV 18,2016 *PED | |
| Pat. No. 6294540 DS* DP* Carbocyclic nucleoside hemisulfate and its use in treating viral infections Claim Types: Composition; Method of use | NOV 14,2018 *PED | U-257: Treatment of HIV infection |
| Pat. No. 6417191 DP* Synergistic combinations of zidovudine, 1592U89 and 3TC Claim Types: Method of use; Composition; Formulation | MAR 28,2016 | U-257: Treatment of HIV infection |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | AUG 02,2007 | D-40: Once-a-day dosing regimen |
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE (TABLET) TRIZIVIR
Drug Classes: ANTIVIRALS
NDA Applicant: GLAXOSMITHKLINE NDA No.: 021205 Prod. No.: 001 RX (EQ 300MG BASE;150MG;300MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5034394 DS* DP* [Extended 905 days (2.5 years)] Therapeutic nucleosides Claim Types: Compound; Composition Comments: For its TRIZIVIR listing, the expiration date of this patent does not include the extension | DEC 26,2009 *PED | |
| Pat. No. 5047407 DS* DP* [Extended 282 days* (0.8 years)] 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties Claim Types: Compound; Composition | MAY 17,2010 *PED | U-248: Treatment of HIV |
| Pat. No. 5089500 Therapeutic nucleosides Claim Types: Method of use | DEC 26,2009 *PED | U-248: Treatment of HIV |
| Pat. No. 5905082 DS* DP* Crystalline oxathiolane derivatives Claim Types: Composition; Method of use | NOV 18,2016 *PED | U-248: Treatment of HIV |
| Pat. No. 6294540 DS* DP* Carbocyclic nucleoside hemisulfate and its use in treating viral infections Claim Types: Composition; Method of use | NOV 14,2018 *PED | U-65: Method of treatment of a patient infected with HIV |
| Pat. No. 6417191 DP* Synergistic combinations of zidovudine, 1592U89 and 3TC Claim Types: Method of use; Composition; Formulation | MAR 28,2016 | U-248: Treatment of HIV |
ABARELIX (INJECTABLE) PLENAXIS
NDA Applicant: PRAECIS NDA No.: 021320 Prod. No.: 001 RX (100MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5843901 DS* DP* LHRH antagonist peptides Claim Types: Compound; Composition | DEC 01,2015 | |
| Pat. No. 5968895 DP* Pharmaceutical formulations for sustained drug delivery Claim Types: Formulation | DEC 11,2016 | |
| Pat. No. 6180608 DP* Pharmaceutical formulations for sustained drug delivery Claim Types: Formulation; Kit; Device; Method of use | DEC 11,2016 | U-549: Use in the treatment of men with advanced symptomatic prostate cancer |
| Pat. No. 6423686 DS* LHRH antagonist peptides Claim Types: Compound | JUN 07,2015 | |
| Pat. No. 6455499 Methods for treating disorders associated with LHRH activity Claim Types: Method of use | JUN 07,2015 | U-549: Use in the treatment of men with advanced symptomatic prostate cancer |
| Pat. No. 6699833 DP* Pharmaceutical formulations for sustained drug delivery Claim Types: Formulation | DEC 11,2016 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | NOV 25,2008 |
ACAMPROSATE CALCIUM (TABLET, DELAYED RELEASE) CAMPRAL
NDA Applicant: FOREST LABS NDA No.: 021431 Prod. No.: 001 RX (333MG)
| Exclusivity | Expiration | Exclusivity Description |
|---|---|---|
| Exclusivity Code: NCE - New chemical entity | JUL 29,2009 |
ACARBOSE (TABLET) PRECOSE
Drug Classes: BLOOD GLUCOSE REGULATORS; DIURETICS
NDA Applicant: BAYER PHARMS NDA No.: 020482 Prod. No.: 001 RX (50MG); 002 RX (100MG); 004 RX (25MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4904769 [Extended 922 days* (2.5 years)] Highly pure acarbose Claim Types: Formulation; Process Comments: Orange Book expiration date does not include extension. Extended expiration date is September 6, 2009. | FEB 27,2007 |
ACETAMINOPHEN (TABLET, EXTENDED RELEASE) TYLENOL (CAPLET) [GENERIC OTC]
NDA Applicant: MCNEIL CONS NDA No.: 019872 Prod. No.: 001 OTC (650MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4820522 Oral sustained release acetaminophen formulation and process Claim Types: Formulation; Process | JUL 27,2007 | |
| Pat. No. 4968509 Oral sustained release acetaminophen formulation and process Claim Types: Formulation; Process | NOV 06,2007 | |
| Pat. No. 5004613 Oral sustained release pharmaceutical formulation and process Claim Types: Formulation; Process | JUL 27,2007 |
ACETAMINOPHEN; ASPIRIN; CAFFEINE (TABLET) EXCEDRIN (MIGRAINE) [GENERIC OTC]
NDA Applicant: NOVARTIS NDA No.: 020802 Prod. No.: 001 OTC (250MG;250MG;65MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4943565 Analgesic tablet of aspirin and caffeine containing low-substituted hydroxypropyl cellulose Claim Types: Formulation | JUL 24,2007 | |
| Pat. No. 5972916 Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine Claim Types: Method of use | JUL 14,2017 | U-296: Treating migraine pain and one or more of a cluster of symptoms characteristic of a migraine attack symptoms being selected from photophobia, phonophobia, nausea and functional disability |
ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE (TABLET) ULTRACET [GENERIC AB]
Drug Classes: ANALGESICS, GENERAL
NDA Applicant: ORTHO MCNEIL PHARM NDA No.: 021123 Prod. No.: 001 RX (325MG;37.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE39221 DS* DP* Composition comprising a tramadol material and acetaminophen and its use Claim Types: Formulation; Method of use | AUG 09,2011 | U-55: Treatment of pain |
ACETYLCHOLINE CHLORIDE (FOR SOLUTION) MIOCHOL-E
Drug Classes: OPHTHALMICS, MISCELLANEOUS
NDA Applicant: NOVARTIS NDA No.: 020213 Prod. No.: 001 RX (20MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 6261546 Methods and compositions for stabilizing acetylcholine compositions Claim Types: Device; Method of use; Process | APR 29,2019 | U-506: Pharm product container 1st chamber is disposed aqueous diluent sol 2nd chamber pharm active agent comprising acetylcholine, buffer in 1st cham is sufficient to buffer pH of mixed sol resulting mixture of aqueous diluent sol & pharm active. |
ACETYLCYSTEINE (INJECTABLE) ACETADOTE
NDA Applicant: CUMBERLAND PHARMS NDA No.: 021539 Prod. No.: 001 RX (6GM/30ML (200MG/ML))
| Exclusivity | Expiration | Exclusivity Description |
|---|---|---|
| Exclusivity Code ODE: Orphan Drug | JAN 23,2011 | For the intravenous treatment of moderate to severe acetaminophen overdose |
ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE (CAPSULE) SEMPREX-D
Drug Classes: COLD REMEDIES
NDA Applicant: UCB INC NDA No.: 019806 Prod. No.: 001 RX (8MG;60MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4650807 [Extended 1469 days (4 years)] Antihistaminic compositions and methods containing pyridine derivatives Claim Types: Composition; Method of use | MAR 26,2008 | U-93: Use as an antihistamine/decongestant |
ACYCLOVIR (CREAM) ZOVIRAX
Drug Classes: ANTIVIRALS
NDA Applicant: GLAXOSMITHKLINE NDA No.: 021478 Prod. No.: 001 RX (5%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4963555 Formulations of heterocyclic compounds Claim Types: Formulation; Method of use | OCT 16,2007 |
ADAPALENE (SOLUTION) DIFFERIN
NDA Applicant: GALDERMA LABS LP NDA No.: 020338 Prod. No.: 001 DISC (0.1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4717720 [Extended 1512 days (4.1 years)] Benzonaphthalene derivatives and compositions Claim Types: Compound; Composition | MAY 31,2010 | |
| Pat. No. RE34440 [Extended 433 days (1.2 years)] Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions Claim Types: Method of use; Composition | MAY 31,2010 | U-275: Method of use of the drug substance |
ADAPALENE (GEL) DIFFERIN
Drug Classes: ACNE PRODUCTS
NDA Applicant: GALDERMA LABS LP NDA No.: 020380 Prod. No.: 001 RX (0.1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4717720 [Extended 1512 days (4.1 years)] Benzonaphthalene derivatives and compositions Claim Types: Compound; Composition | MAY 31,2010 | |
| Pat. No. RE34440 [Extended 433 days (1.2 years)] Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions Claim Types: Method of use; Composition | MAY 31,2010 | U-275: Method of use of the drug substance |
ADAPALENE (CREAM) DIFFERIN
NDA Applicant: GALDERMA LABS LP NDA No.: 020748 Prod. No.: 001 RX (0.1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4717720 [Extended 1512 days (4.1 years)] Benzonaphthalene derivatives and compositions Claim Types: Compound; Composition | MAY 31,2010 | |
| Pat. No. RE34440 [Extended 433 days (1.2 years)] Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions Claim Types: Method of use; Composition | MAY 31,2010 | U-275: Method of use of the drug substance |
ADEFOVIR DIPIVOXIL (TABLET) HEPSERA
NDA Applicant: GILEAD NDA No.: 021449 Prod. No.: 001 RX (10MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4724233 Therapeutical application of phosphonylmethoxyalkyl adenines Claim Types: Method of use | APR 21,2006 | U-470: Therapy in chronic hepatitis B virus infection |
| Pat. No. 4808716 9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof Claim Types: Compound | APR 25,2006 | |
| Pat. No. 5663159 DS* DP* Prodrugs of phosphonates Claim Types: Compound; Method of use | SEP 02,2014 | U-470: Therapy in chronic hepatitis B virus infection |
| Pat. No. 6451340 DS* DP* Nucleotide analog compositions Claim Types: New polymorph, salt or hydrate; Method of use; Process; Product-by-process; Formulation | JUL 23,2018 | U-470: Therapy in chronic hepatitis B virus infection |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | SEP 20,2007 |
ADENOSINE (INJECTABLE) ADENOSCAN [Has competitive generic]
Drug Classes: ANTIARRHYTHMICS
NDA Applicant: ASTELLAS NDA No.: 020059 Prod. No.: 001 RX (3MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5070877 [Extended 159 days* (0.4 years)] Novel method of myocardial imaging Claim Types: Diagnostic or surgical method | MAY 18,2009 | U-116: Method of myocardial imaging |
| Pat. No. 5731296 Selective vasodilation by continuous adenosine infusion Claim Types: Method of use | MAR 24,2015 | U-221: Selective vasodilation by continuous adenosine infusion |
ALATROFLOXACIN MESYLATE (INJECTABLE) TROVAN PRESERVATIVE FREE
NDA Applicant: PFIZER NDA No.: 020760 Prod. No.: 001 DISC (EQ 200MG BASE/VIAL); 002 DISC (EQ 300MG BASE/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5164402 [Extended 761 days* (2.1 years)] Azabicyclo quinolone and naphthyridinone carboxylic acids Claim Types: Compound; Composition; Method of use Comments: Orange Book expiration date for TROVAN PRESERVATIVE FREE does not include extension. Extended expiration date is December 18, 2011. | NOV 17,2009 | U-282: Method of treating bacterial infections |
| Pat. No. 5763454 Crystal form of anhydrous 7-(ý1.alpha.,5.alpha.,6.alpha.!-6-amino-3-azabicycloý3.1.0! hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt Claim Types: New polymorph, salt or hydrate; Composition; Method of use | JUN 15,2015 | U-282: Method of treating bacterial infections |
| Pat. No. 6080756 Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin Claim Types: New polymorph, salt or hydrate; Method of use; Composition | JUL 05,2016 | |
| Pat. No. 6194429 Alatrofloxacin parenteral compositions Claim Types: Compound; Formulation; Process; Composition; Method of use | JUL 23,2018 |
ALBUMIN HUMAN (INJECTABLE) OPTISON
Drug Classes: BLOOD COMPONENTS/SUBSTITUTES
NDA Applicant: GE HEALTHCARE NDA No.: 020899 Prod. No.: 001 RX (10MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5529766 Contrast agents Claim Types: Diagnostic or surgical method; Formulation; Process | JUN 25,2013 | U-505: Ultrasound contrast agent |
| Pat. No. 5558094 Methods for using persistent gases as ultrasound contrast media Claim Types: Diagnostic or surgical method | FEB 28,2012 | U-505: Ultrasound contrast agent |
| Pat. No. 5573751 Persistent gaseous bubbles as ultrasound contrast media Claim Types: Composition; Formulation | APR 25,2012 | |
| Pat. No. 6723303 DP* Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane Claim Types: Composition | APR 20,2021 |
ALBUTEROL SULFATE (AEROSOL, METERED) PROVENTIL-HFA
Drug Classes: ANTIASTHMATICS/BRONCODILATORS
NDA Applicant: 3M NDA No.: 020503 Prod. No.: 001 RX (EQ 0.09MG BASE/INH)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5225183 Medicinal aerosol formulations Claim Types: Formulation | JUL 06,2010 | |
| Pat. No. 5439670 Medicinal aerosol formulations Claim Types: Formulation | JUL 06,2010 | |
| Pat. No. 5605674 Medicinal aerosol formulations Claim Types: Formulation | FEB 25,2014 | |
| Pat. No. 5695743 Medicinal aerosol formulations Claim Types: Formulation; Method of administration; Method of use | JUL 06,2010 | U-491: Method of delivering a drug to the lung |
| Pat. No. 5766573 Medicinal aerosol formulations Claim Types: Method of administration | JUN 16,2015 | |
| Pat. No. 6352684 CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant Claim Types: Formulation | NOV 28,2009 |
ALBUTEROL SULFATE (SOLUTION) ACCUNEB [GENERIC AN]
Drug Classes: ANTIASTHMATICS/BRONCODILATORS
NDA Applicant: DEY NDA No.: 020949 Prod. No.: 001 RX (EQ 0.042% BASE); 002 RX (EQ 0.021% BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 6702997 Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma Claim Types: Method of use | DEC 28,2021 | U-558: Indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease) |
ALBUTEROL SULFATE (AEROSOL, METERED) VENTOLIN HFA
NDA Applicant: GLAXOSMITHKLINE NDA No.: 020983 Prod. No.: 001 RX (EQ 0.09MG BASE/INH)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 6131566 DP* Metered dose inhaler for albuterol Claim Types: Device; Method of administration | APR 14,2015 | U-589: Method for treatment of a respiratory disorder, e.g., bronchospasm, comprising administering an effective amount of an aerosol composition to a patient from a metered dose inhaler system as claimed in U.S. Patent No. 6131966 |
| Pat. No. 6131566 DP* Metered dose inhaler for albuterol Claim Types: Device; Method of administration | APR 14,2015 | U-716: The treatment or prevention of bronchospasm in adults and children 4 years of age and older with reversible obstructive airways disease and the prevention of exercised-induced bronchospasm in patients 4 years of age and older |
| Pat. No. 6315173 DP* Valve for aerosol container Claim Types: Device | DEC 23,2017 | |
| Pat. No. 6510969 DP* Valve for aerosol container Claim Types: Device | DEC 23,2017 | |
| Pat. No. 6532955 DP* Metered dose inhaler for albuterol Claim Types: Device; Method of administration | APR 14,2015 | U-590: Method for treatment of a respiratory disorder,e.g.,bronchospasm,comprising administering to a patient by oral or nasal inhalation a drug formulation by using the metered dose inhaler system as claimed in U.S. Patent No.6532955 |
| Pat. No. 6532955 DP* Metered dose inhaler for albuterol Claim Types: Device; Method of administration | APR 14,2015 | U-716: The treatment or prevention of bronchospasm in adults and children 4 years of age and older with reversible obstructive airways disease and the prevention of exercised-induced bronchospasm in patients 4 years of age and older |
ALBUTEROL SULFATE (AEROSOL, METERED) PROAIR HFA
NDA Applicant: IVAX RES NDA No.: 021457 Prod. No.: 001 RX (EQ 0.09MG BASE/INH)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5605674 DP* Medicinal aerosol formulations Claim Types: Formulation | FEB 25,2014 | |
| Pat. No. 5695743 DP* Medicinal aerosol formulations Claim Types: Formulation; Method of administration; Method of use | JUL 06,2010 | U-491: Method of delivering a drug to the lung |
| Pat. No. 5766573 Medicinal aerosol formulations Claim Types: Method of administration | NOV 28,2009 | U-356: Delivering a medicinal aerosol formulation using CFC-free propellant 134a. |
| Pat. No. 6352684 DP* CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant Claim Types: Formulation | NOV 28,2009 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | FEB 03,2009 | I-235: Prevention of exercise-induced bronchospasm in patients 12 years of age and older |
| Exclusivity Code: NP - New product | OCT 29,2007 |
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE (AEROSOL, METERED) COMBIVENT
Drug Classes: ANTIASTHMATICS/BRONCODILATORS
NDA Applicant: BOEHRINGER INGELHEIM NDA No.: 020291 Prod. No.: 001 RX (EQ 0.09MG BASE/INH;0.018MG/INH)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5603918 Aerosol composition of a salt of ipratropium and a salt of albuterol Claim Types: Formulation; Process | JUN 09,2015 |
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE (SOLUTION) DUONEB
Drug Classes: ANTIASTHMATICS/BRONCODILATORS
NDA Applicant: DEY NDA No.: 020950 Prod. No.: 001 RX (EQ 0.083% BASE;0.017%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 6632842 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease Claim Types: Method of improving a treatment | DEC 28,2021 | U-532: Treatment of bronchospasm associated with COPD in patients requiring more than one broncho dilator |
ALCOHOL; CHLORHEXIDINE GLUCONATE (SOLUTION) AVAGARD
NDA Applicant: 3M NDA No.: 021074 Prod. No.: 001 OTC (61%;1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5897031 Dispenser for antimicrobial liquids Claim Types: Device; Method of using a device | JUN 21,2016 |
ALENDRONATE SODIUM (TABLET) FOSAMAX
Drug Classes: CALCIUM METABOLISM
NDA Applicant: MERCK NDA No.: 020560 Prod. No.: 001 RX (EQ 10MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4621077 [Extended 1371 days (3.8 years)] Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom Claim Types: Method of use | FEB 06,2008 *PED | U-114: Use for inhibiting bone resorption |
| Pat. No. 5358941 Dry mix formulation for bisphosphonic acids with lactose Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 5681590 Dry mix formulation for bisphosphonic acids Claim Types: Formulation; Process | JUN 02,2013 *PED | |
| Pat. No. 5849726 Anhydrous alendronate monosodium salt formulations Claim Types: Composition; Method of use | DEC 06,2015 *PED | |
| Pat. No. 6008207 Anhydrous alendronate monosodium salt formulations Claim Types: Method of use | DEC 06,2015 *PED | U-303: Method of use patent-product approved for treatment of osteoporosis, Paget's disease, prevention and treatment of glucocorticoid-induced osteoporosis |
| Pat. No. 6090410 Dry mix formulation for bisphosphonic acids Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 6194004 Dry mix formulation for bisphosphonic acids Claim Types: Formulation | JUN 02,2013 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: M - Miscellaneous | DEC 21,2008 | M-51: Information added to labeling regarding osteogenesis imperfecta study |
ALENDRONATE SODIUM (TABLET) FOSAMAX
Drug Classes: CALCIUM METABOLISM
NDA Applicant: MERCK NDA No.: 020560 Prod. No.: 002 RX (EQ 40MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4621077 [Extended 1371 days (3.8 years)] Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom Claim Types: Method of use | FEB 06,2008 *PED | U-114: Use for inhibiting bone resorption |
| Pat. No. 5358941 Dry mix formulation for bisphosphonic acids with lactose Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 5681590 Dry mix formulation for bisphosphonic acids Claim Types: Formulation; Process | JUN 02,2013 *PED | |
| Pat. No. 5849726 Anhydrous alendronate monosodium salt formulations Claim Types: Composition; Method of use | DEC 06,2015 *PED | |
| Pat. No. 6008207 Anhydrous alendronate monosodium salt formulations Claim Types: Method of use | JUN 06,2015 *PED | U-303: Method of use patent-product approved for treatment of osteoporosis, Paget's disease, prevention and treatment of glucocorticoid-induced osteoporosis |
| Pat. No. 6090410 Dry mix formulation for bisphosphonic acids Claim Types: Formulation | JUN 02,2013 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: M - Miscellaneous | DEC 21,2008 | M-51: Information added to labeling regarding osteogenesis imperfecta study |
ALENDRONATE SODIUM (TABLET) FOSAMAX
Drug Classes: CALCIUM METABOLISM
NDA Applicant: MERCK NDA No.: 020560 Prod. No.: 003 RX (EQ 5MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4621077 [Extended 1371 days (3.8 years)] Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom Claim Types: Method of use | FEB 06,2008 *PED | U-114: Use for inhibiting bone resorption |
| Pat. No. 5358941 Dry mix formulation for bisphosphonic acids with lactose Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 5681590 Dry mix formulation for bisphosphonic acids Claim Types: Formulation; Process | JUN 02,2013 *PED | |
| Pat. No. 5849726 Anhydrous alendronate monosodium salt formulations Claim Types: Composition; Method of use | DEC 06,2015 *PED | |
| Pat. No. 6008207 Anhydrous alendronate monosodium salt formulations Claim Types: Method of use | DEC 06,2015 *PED | U-303: Method of use patent-product approved for treatment of osteoporosis, Paget's disease, prevention and treatment of glucocorticoid-induced osteoporosis |
| Pat. No. 6090410 Dry mix formulation for bisphosphonic acids Claim Types: Formulation | JUN 02,2013 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: M - Miscellaneous | DEC 21,2008 | M-51: Information added to labeling regarding osteogenesis imperfecta study |
ALENDRONATE SODIUM (TABLET) FOSAMAX
Drug Classes: CALCIUM METABOLISM
NDA Applicant: MERCK NDA No.: 020560 Prod. No.: 004 RX (EQ 35MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4621077 [Extended 1371 days (3.8 years)] Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom Claim Types: Method of use | FEB 06,2008 *PED | U-114: Use for inhibiting bone resorption |
| Pat. No. 5358941 Dry mix formulation for bisphosphonic acids with lactose Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 5681590 Dry mix formulation for bisphosphonic acids Claim Types: Formulation; Process | JUN 02,2013 *PED | |
| Pat. No. 5849726 Anhydrous alendronate monosodium salt formulations Claim Types: Composition; Method of use | DEC 16,2015 *PED | |
| Pat. No. 5994329 Method for inhibiting bone resorption Claim Types: Method of use; Kit | JAN 17,2019 *PED | |
| Pat. No. 6008207 Anhydrous alendronate monosodium salt formulations Claim Types: Method of use | DEC 06,2015 *PED | |
| Pat. No. 6015801 Method for inhibiting bone resorption Claim Types: Method of use | JAN 17,2019 *PED | U-353: Prevention and treatment of osteoporosis |
| Pat. No. 6090410 Dry mix formulation for bisphosphonic acids Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 6225294 Method for inhibiting bone resorption Claim Types: Kit | JAN 17,2019 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: M - Miscellaneous | DEC 21,2008 | M-51: Information added to labeling regarding osteogenesis imperfecta study |
ALENDRONATE SODIUM (TABLET) FOSAMAX
Drug Classes: CALCIUM METABOLISM
NDA Applicant: MERCK NDA No.: 020560 Prod. No.: 005 RX (EQ 70MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4621077 [Extended 1371 days (3.8 years)] Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom Claim Types: Method of use | FEB 06,2008 *PED | U-114: Use for inhibiting bone resorption |
| Pat. No. 5358941 Dry mix formulation for bisphosphonic acids with lactose Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 5681590 Dry mix formulation for bisphosphonic acids Claim Types: Formulation; Process | JUN 02,2013 *PED | |
| Pat. No. 5849726 Anhydrous alendronate monosodium salt formulations Claim Types: Composition; Method of use | DEC 06,2015 *PED | |
| Pat. No. 5994329 Method for inhibiting bone resorption Claim Types: Method of use; Kit | JAN 17,2019 *PED | |
| Pat. No. 6008207 Anhydrous alendronate monosodium salt formulations Claim Types: Method of use | DEC 06,2015 *PED | |
| Pat. No. 6015801 Method for inhibiting bone resorption Claim Types: Method of use | JAN 17,2019 *PED | U-353: Prevention and treatment of osteoporosis |
| Pat. No. 6090410 Dry mix formulation for bisphosphonic acids Claim Types: Formulation | JUN 02,2013 *PED | |
| Pat. No. 6225294 Method for inhibiting bone resorption Claim Types: Kit | JAN 17,2019 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | APR 16,2007 | D-87: Addition of once-weekly dosing for the treatment to increase bone mass in men with osteoporosis |
| Exclusivity Code: M - Miscellaneous | DEC 21,2008 | M-51: Information added to labeling regarding osteogenesis imperfecta study |
ALENDRONATE SODIUM (SOLUTION) FOSAMAX
NDA Applicant: MERCK NDA No.: 021575 Prod. No.: 001 RX (EQ 70MG BASE/75ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4621077 [Extended 1371 days (3.8 years)] Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom Claim Types: Method of use | FEB 06,2008 *PED | |
| Pat. No. 5462932 Oral liquid alendronate formulations Claim Types: Formulation; Method of use | MAY 17,2014 | |
| Pat. No. 5994329 Method for inhibiting bone resorption Claim Types: Method of use; Kit | JAN 17,2019 *PED | |
| Pat. No. 6015801 Method for inhibiting bone resorption Claim Types: Method of use | JAN 17,2019 *PED | |
| Pat. No. |